Investigating how a protein affects immune cell behavior in lung disease.
Role of ADAM17 in MDSC-Mediated Development of Pulmonary Hypertension
This study is looking at how a protein called ADAM17 helps attract certain immune cells in the lungs that may play a role in pulmonary hypertension, with the hope that understanding this process can lead to new ways to treat the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project ID | NIH-10816571 on NIH RePORTER |
What this research studies
This research explores the role of a protein called ADAM17 in the recruitment of immune cells that contribute to pulmonary hypertension (PH). By studying how ADAM17 influences the movement of myeloid-derived suppressor cells (MDSCs) in the lungs, the researchers aim to understand the mechanisms behind PH development. The approach involves using animal models to observe the effects of ADAM17 on immune cell behavior and its relationship with a specific receptor known as CXCR2. This knowledge could lead to new therapeutic strategies for managing PH.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pulmonary hypertension or related lung conditions.
Not a fit: Patients with conditions unrelated to pulmonary hypertension or those who do not have a significant immune component to their disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that better manage or prevent pulmonary hypertension.
How similar studies have performed: Previous research has shown that targeting immune cell behavior can be effective in treating similar conditions, suggesting potential for success in this approach.
Where this research is happening
Gainesville, United States
- University of Florida — Gainesville, United States (Active)
Researchers
- Principal investigator: Bryant, Andrew Justin — University of Florida
- Study coordinator: Bryant, Andrew Justin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.